Gastric Adenocarcinoma
Conditions
Brief summary
In previous studies, we found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer. Apatinib is an orally antiangiogenic agent. It was approved and launched in China in 2014 as a 3rd-line treatment for patients with advanced gastric cancer. Therefore, investigators initialize this dose escalation phase I study to explore the safety of combination of apatinib and POF as first-line treatment for advanced gastric cancer. Investigators will analyze the maximum tolerated dose (MDT) and dose-limiting toxicity (DLT) of apatinib in this study.
Interventions
DRUGApatinib
Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects). Other Name:
DRUGPOF
The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with advanced unresectable, histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction. 2. No previous treatment with chemotherapy or radiation therapy. 3. Ability to take medications orally. 4. With or without measurable lesions. 5. Patients must have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. 6. Without serious system dysfunction and could tolerate chemotherapy. With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a leucopenia count of ≥4.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis. 7. Life expectancy ≥3 months. 8. With normal electrocardiogram results and no history of congestive heart failure. 9. Without bleeding and thrombosis disease. 10. With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN. 11. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug 12. With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors. 13. With good compliance and agree to accept follow-up of disease progression and adverse events.
Exclusion criteria
1. Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer. 2. Patients with brain or central nervous system metastases, including leptomeningeal disease. 3. Pregnant (positive pregnancy test) or breast feeding. 4. Serious, non-healing wound, ulcer, or bone fracture. 5. Significant cardiac disease as defined as: unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy. 6. History of a stroke or CVA within 6 months. 7. Clinically significant peripheral vascular disease. 8. Inability to comply with study and/or follow-up procedures. 9. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicity | From enrollment to completion of study. Estimated about 12 months. | Dose limiting toxicity (DLT) is referred to grade 3 non-hematological toxicity or grade 4 hematological toxicity according to NCI CTCAE 4.03 criteria |
| Maximum tolerance dose | From enrollment to completion of study. Estimated about 12 months. | Maximum tolerance dose (MTD) is the dose of treatment in the cohort where there are 2 cases of DTL reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | From enrollment to 3 months after treatment | Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate). |
| Progression-free survival | From enrollment to progression of disease. Estimated about 6 months. | The length of time from enrollment until the time of progression of disease (PFS, progression-free survival). |
| Overall survival | From enrollment to death of patients. Estimated about 1 year. | The length of time from enrollment until the time of death (OS, overall survival). |
Countries
China
Contacts
Primary ContactRongbo Lin
Outcome results
None listed